This study was presented in the 24th European CF Conference (Vienna, Austria 6–9 June 2001).
Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis1
Article first published online: 10 FEB 2006
Journal of Clinical Pharmacy and Therapeutics
Volume 31, Issue 1, pages 49–55, February 2006
How to Cite
Yalçın, E., Kiper, N., Özçelik, U., Doǧru, D., Fırat, P., Şahin, A., Arıyürek, M., Mocan, G., Gürcan, N. and Göçmen, A. (2006), Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics, 31: 49–55. doi: 10.1111/j.1365-2710.2006.00708.x
- Issue published online: 10 FEB 2006
- Article first published online: 10 FEB 2006
- Received 21 November 2004, Accepted 15 April 2005
Background: The effects of the macrolides cannot be ascribed to their antibacterial action alone. Their immunoregulatory and anti-inflammatory functions are significant too. They are frequently used in the treatment of diffuse panbronchiolitis and cystic fibrosis (CF).
Aim: To evaluate the effects of a macrolide antibiotic [clarithromycin (CAM)] on the process of inflammation [by measuring IL-8, TNF-α, IL-10 levels and cell profiles in bronchoalveolar lavage (BAL) fluid], pulmonary function and sputum production in children with steady-state bronchiectasis, secondary to causes other than CF or primary immunodeficiencies.
Methods: Seventeen patients randomized to the treatment group received CAM and supportive therapies for 3 months and 17 patients in the control group were given supportive therapies only.
Results: Compared with the control group, the treatment group showed a significant decrease in IL-8 levels, total cell count, neutrophil ratios in BAL fluid and daily sputum production at the end of the third month. There was also a significant increase in the treatment group's BAL fluid macrophage ratios. The differences in pulmonary function test parameters were not significant.
Conclusion: Use of CAM in children with steady-state bronchiectasis results in laboratory improvement by reducing the inflammatory processes in the lungs. No corresponding clinical improvement could be shown but although this is possible with long-term use, trial validation is necessary.